Hormonal
Retatrutide increases the rate of gastrointestinal adverse events (nausea, vomiting, constipation) and hypersensitivity reactions compared to placebo, but does not significantly increase serious adverse events.
Be aware that retatrutide is more likely to cause nausea, vomiting, and constipation than a placebo. However, these are typically not 'serious' adverse events, and the drug does not appear to increase the risk of serious health complications or death compared to no treatment. Monitor your symptoms and communicate with your doctor.
Compared with placebo, retatrutide significantly increased the rate of TEAEs (RR 1.18; 95 % CI 1.04–1.35; p = 0.01; I2 = 0 %; Supplementary Material 1, Fig. S5A), nausea (RR 2.68; 95 % CI 1.54–4.68; p < 0.01; I2 = 0 %; Supplementary Material 1, Fig. S5B), vomiting (RR 4.59; 95 % CI 1.30–16.24; p = 0.02; I2 = 0 %; Supplementary Material 1, Fig. S5C), constipation (RR 3.08; 95 % CI 1.12–8.45; p = 0.03; I2 = 0 %; Supplementary Material 1, Fig. S5D), and hypersensitivity (RR 3.79; 95 % CI 1.20–11.96; p = 0.02; I2 = 0 %; Supplementary Material 1, Fig. S6A). There was no significant difference between groups for serious adverse events (RR 1.46; 95 % CI 0.46–4.61; p = 0.52 I2 = 49 %; Supplementary Material 1, Fig. S6B).
Why this rating
Based on 3 RCTs with low heterogeneity for most adverse events (I2=0%) and low risk of bias.
Source
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials
Eric Pasqualotto et al. · Metabolism Open · 2024
DOI 10.1016/j.metop.2024.100321
More from this paper
- Once-weekly subcutaneous retatrutide significantly reduces body weight, BMI, and waist circumference in patients with overweight, obesity, and/or type 2 diabetes compared to placebo.Moderate
- Retatrutide significantly improves glycemic control, including reductions in HbA1c, fasting glucose, and daily mean blood glucose, in patients with obesity and/or type 2 diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →